OBJECTIVE:
The window of opportunity to treat congenital CMV is narrow and therefore CMV infection should be tested early when risk factors arise., It has been suggested that polyhydramnios is associated with CMV infection, resulting in polyhydramnios being the most common indication for CMV testing. Possible mechanisms include impaired swallowing due to CNS injury, polyuria via renal infection, and fetal malformations. However, this subject was examined only in small studies with methodological limitations that failed to demonstrate a clear association between polyhydramnios and CMV infection. We aimed to examine the association between congenital CMV infection and polyhydramnios. STUDY DESIGN: A retrospective cross-sectional cohort study was conducted between January 2013 and December 2017. In our center polyhydramnios is not an indication for CMV testing. The rate of polyhydramnios was analyzed in 61 neonates and 2 fetuses that tested positive for CMV infection between 2013 and 2017 and compared to 351 neonates who tested negative to CMV using PCR targeted to the viral DNA. The rate of oligohydramnios and small for gestational age was also evaluated. The sample size was calculated assuming that the rate of polyhydramnios is 2% versus 10% in the negative and positive CMV infection groups, respectively (80% power, 5% 2-sided alpha). RESULTS: The indications for CMV testing are presented in the figure. Study characteristics and outcomes are presented in the table. No statistically significant difference in the rate of polyhydramnios, oligohydramnios or small for gestational age neonate was found in fetuses/neonates with and without congenital CMV. There were no cases of polyhydramnios combined with fetal malformations. CONCLUSION: The results of this study do not support an association between CMV infection and polyhydramnios. The need for antenatal or postnatal CMV testing in isolated polyhydramnios should be reevaluated.
632 Long-term infectious morbidity of offspring born to women who conceived with an intrauterine contraceptive device 
The intrauterine device (IUD) is a commonly used method of reversible contraception worldwide. Pregnancy with an IUD in situ is a risk factor for adverse pregnancy outcome. The purpose of the current study was to examine a possible association between the presence of IUD during pregnancy and long-term infectious morbidity of the offspring. STUDY DESIGN: A population-based cohort analysis was performed including all singleton deliveries occurring between 1991-2014 at a single tertiary medical center. The primary exposure was defined as delivery of an infant to a mother conceived with an IUD that has been either removed or has not been removed. Offspring of mothers who conceived without an IUD comprised the comparison (unexposed) group. The main outcome evaluated was infectious morbidity of the offspring up to the age of 18 years. A Kaplan-Meier survival curve was used to compare cumulative infectious morbidity incidence. A Cox proportional hazards model was conducted to control for confounders. RESULTS: During the study period 220,709 deliveries met the inclusion criteria, of which 0.09% (n¼ 199) were born to mothers who conceived with an IUD that was removed, and 0.06% (n¼147) were born to mothers with a retained IUD. Long-term infections morbidity was comparable between the groups (12.2% in offspring to women with retained IUD, 12.1 % in the group of removed IUD, and 10.2% in the no-IUD group; P ¼ 0.47; Table) . Likewise, the Kaplan-Meier survival curve did not demonstrate a significantly higher cumulative incidence of infectious morbidity in offspring of women conceiving with an IUD (Figure, log rank p¼0.233 ). In the Cox regression model, while controlling for confounders such as maternal age and preterm birth, delivery of a neonate to mother with an IUD was not found to be independently associated with longterm infectious morbidity of the offspring. CONCLUSION: Offspring of women conceiving with an intrauterine contraceptive device are not at an increased risk for long-term infectious morbidity.
